CAPRICOR THERAPEUTICS, INC.CAPREarnings & Financial Report
Nasdaq
CAPR Q4 2024 Key Financial Metrics
Revenue
$11.1M
Gross Profit
N/A
Operating Profit
$-7.7M
Net Profit
$-7.1M
Gross Margin
N/A
Operating Margin
-69.2%
Net Margin
-63.9%
YoY Growth
-7.9%
EPS
$-0.11
Financial Flow
CAPRICOR THERAPEUTICS, INC. Q4 2024 Financial Summary
CAPRICOR THERAPEUTICS, INC. reported revenue of $11.1M for Q4 2024, with a net profit of $-7.1M (-63.9% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $11.1M |
|---|---|
| Net Profit | $-7.1M |
| Gross Margin | N/A |
| Operating Margin | -69.2% |
| Report Period | Q4 2024 |
CAPRICOR THERAPEUTICS, INC. Annual Revenue by Year
CAPRICOR THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $22.3M).
| Year | Annual Revenue |
|---|---|
| 2024 | $22.3M |
| 2023 | $25.2M |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $3.9M | $6.2M | $12.1M | $4.9M | $4.0M | $2.3M | $11.1M |
| YoY Growth | N/A | N/A | 288.7% | N/A | 64.3% | 1.4% | -63.4% | -7.9% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $53.9M | $46.0M | $37.2M | $58.7M | $49.4M | $38.3M | $93.0M | $170.5M |
| Liabilities | $47.7M | $43.3M | $38.9M | $36.1M | $31.0M | $26.8M | $24.7M | $25.0M |
| Equity | $6.2M | $2.7M | $-1.8M | $22.6M | $18.4M | $11.5M | $68.3M | $145.5M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $4.2M | $-9.4M | $-8.8M | $-11.6M | $-1.3M | $-12.3M | $-11.6M | $-14.8M |